Welcome to La Jolla Pharmaceutical Company, where we're dedicated to developing treatments that significantly improve outcomes in patients with life threatening diseases.

Learn More


Our current efforts focus on the clinical evaluation of treatments for chronic organ disease and hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure....

Learn More

scientist working at the laboratory

Our researchers are focused on expanding our pipeline by developing innovative new therapies...

Learn More

Our Leading Drug Candidates: LJPC-501, GCS-100, LJPC1010, and LJPC-401

Our drug development efforts are focused on four product candidates, LJPC-501GCS-100LJPC-1010, and LJPC-401.  Our lead product, LJPC-501, is a peptide agonist of the renin-angiotensin system that acts to help the kidneys balance body fluids and electrolytes. Our second product candidate, GCS-100, focuses on modulation of galectin-3, a member of the galectin family of proteins.  Our third product candidate, LJPC-1010 is a more potent and purified derivative of GCS-100 that can be delivered orally.  Our fourth product candidate, LJPC-401, is a formulation of Hepcidin, a endogenous peptide hormone that regulates dietary iron absorption and tissue distribution.